Global Antiviral Drug Resistance Market to amass US $4,573.24 Mn by 2027

December 09, 2019


According to the latest study titled ‘Antiviral Drug Resistance Market to 2027 - Global Analysis and Forecasts By Product (Kits & Reagents and Instruments), Disease Indication (Human Immunodeficiency Virus [HIV], Hepatitis and Cytomegalovirus [CMV]), Technology (Immunodiagnostics, Polymerase Chain Reaction [PCR], Next Generation Sequencing [NGS], and Other Technologies), End User (Hospitals & Clinics, Pathology or Diagnostic Laboratories and Research Institutes), and Geography’ available with Market Study Report LLC, the global antiviral drug resistance market is estimated to accumulate US $4,573.24 million by the year 2027.
 

Antiviral drug resistance is a rising concern among the immunocompromised patients and refers to the drugs that have either lost their effectiveness or have been diminished against the virus to be targeted. Factors such as surging incidences of hepatitis disease and rising prevalence of HIV/AIDS are aiding to the growth of antiviral drug resistance market. However, the availability of alternative approaches may limit the growth of the market to a certain extent.
 

According to the study, the global antiviral drug resistance market was valued at US $2,572.26 million in 2018 and is anticipated to register a growth rate of 6.8 % through the year 2027. The study encompasses details about market size based on revenue shares for each segment, alongside the expansion strategies adopted by manufacturers. Information about the market dynamics covering drivers and restraints is also outlined in the report. 
 

Based on product, antiviral drug resistance market is segmented into kits & reagents and instruments. While as per disease indication, the industry is divided into human immunodeficiency virus (HIV) and CMV hepatitis. Speaking of technology, antiviral drug resistance market is split into immunodiagnostics, next generation sequencing (NGS), polymerase chain reaction (PCR), and other technologies.
 

Request sample copy of this Report@ https://www.marketstudyreport.com/request-a-sample/2202042/
 

In terms of end-user spectrum, antiviral drug resistance market is bifurcated into pathology or diagnostic laboratories, hospitals & clinics, and research institutes. Considering the geographical landscape, the global antiviral drug resistance market is fragmented into regions as North America, Europe, APAC, Middle East & Africa, and South & Central America.
 

Some of the vendors that operate in antiviral drug resistance market are Trinity Biotech, F. Hoffmann-La Roche Ltd., BD, Abbott, Danaher, Bio-Rad Laboratories, Inc., BioMerieux SA, Siemens AG, ACON Laboratories, Inc., and AccuBioTech Co., Ltd.


Frequently Asked Questions (FAQ) :

Antiviral drug resistance is a rising concern among the immunocompromised patients and refers to the drugs that have either lost their effectiveness or have been diminished against the virus to be targeted. Factors such as rising incidences of hepatitis disease and surging prevalence of HIV/AIDS are aiding to the growth of antiviral drug resistance market.
The global antiviral drug resistance market is estimated to accumulate US $4,573.24 million by 2027. The resistance market was valued at US $2,572.26 million in 2018 and is anticipated to register a growth rate of 6.8 % through the year 2027.
Based on product, antiviral drug resistance market is segmented into kits & reagents and instruments. While as per disease indication, the industry is divided into human immunodeficiency virus (HIV) and CMV hepatitis. Speaking of technology, antiviral drug resistance market is split into immunodiagnostics, next generation sequencing (NGS), polymerase chain reaction (PCR), and other technologies. In terms of end-user spectrum, antiviral drug resistance market is bifurcated into hospitals & clinics, pathology or diagnostic laboratories, and research institutes.
Companies that show prominence in the competitive landscape of antiviral drug resistance market are Trinity Biotech, F. Hoffmann-La Roche Ltd., BD, Abbott, Danaher, Bio-Rad Laboratories, Inc., BioMerieux SA, Siemens AG, ACON Laboratories, Inc., and AccuBioTech Co. Ltd.